Travere Therapeutics (TVTX) stock is in focus after the company reported its first non-GAAP profitable quarter, coinciding with long term FILSPARI data from the Phase 3 DUPLEX Study in focal segmental glomerulosclerosis.

The recent 1-day share price return of 6.4% to US$52.04 caps a sharp run, with a 90-day share price return of 85.66% and a 1-year total shareholder return of roughly 3.6x. This suggests momentum is building as the market reacts to the first non-GAAP profitable quarter, long term FILSPARI data, and recent hiring-linked equity grants.

If you are looking beyond Travere and want to see what else is moving in high growth areas, this could be a good moment to scan 40 healthcare AI stocks.

With Travere now reporting its first non-GAAP profitable quarter, alongside a rapid share price move and an intrinsic value estimate that sits below the current market price, the key question is whether there is still an opportunity for investors to establish or add to a position, or if the market is already fully reflecting expectations for future growth.

Most Popular Narrative: 2.9% Undervalued

The most followed narrative puts Travere Therapeutics' fair value at $53.57, slightly above the last close at $52.04, framing a modest undervaluation and tying that gap directly to expectations for FILSPARI led growth and margins.

Travere's strengthening financial position, driven by rapid product sales growth, increased international out-licensing revenues, significant reductions in net losses, and prudent R&D and SG&A management, sets a foundation for positive net earnings and secures resources for continued pipeline development and future commercial launches. (Earnings, cash flow, R&D investment)

Want to see what is sitting behind that fair value uplift? Revenue expansion, margin reset, and a future earnings multiple all work together here. The exact mix, and the outer year profit profile it implies, might surprise you.

Result: Fair Value of $53.57 (UNDERVALUED)

However, the story cuts both ways, with heavy reliance on FILSPARI, and potential pricing or regulatory pressure that could quickly challenge the current fair value narrative.

Next Steps

With sentiment split between the upside potential and the risks raised in recent data and narratives, this is a good time to review the underlying numbers yourself and decide how you feel about the balance of concerns and opportunities, then head over to the 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

If you stop with just one stock, you could miss opportunities that fit your goals better, so put a few more ideas on your radar now.

• Hunt for mispriced quality by scanning 44 high quality undervalued stocks that combine solid fundamentals with potentially appealing entry points.
• Prioritize staying power by reviewing solid balance sheet and fundamentals stocks screener (48 results) that aim to pair financial resilience with room for growth.
• Get ahead of the crowd by checking the screener containing 20 high quality undiscovered gems that most investors may not be watching yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.